Search Results

Prolacta Bioscience announced that data demonstrating the benefits of Prolacta’s Exclusive Human Milk Diet for term infants recovering from gastroschisis repair surgery will be presented at the European Society for Paediatric Gastroenterology Hepatology and Nutrition meeting in Milan, Italy, taking place May 15-18.

Prolacta Bioscience®, the world’s leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced today that top-ranked analyst David Steinberg has been appointed as chief financial officer.

Prolacta Bioscience® announced the introduction of the first evidence-based feeding protocol for the use of an Exclusive Human Milk Diet including Prolacta’s products in the neonatal intensive care unit.

Prolacta Bioscience ®, the world’s leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, celebrated Breastfeeding Awareness Month by recognizing the commitment of NICU parents to their infants’ health through advocating for and/or providing essential human milk nutrition.

Prolacta Bioscience®, the world’s leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced today that neonatologist and breastfeeding advocate Erin Hamilton Spence, MD, IBCLC, has been appointed director of clinical education and professional development.

Prolacta Bioscience® announced the publication of a journal article that showed improved long-term neurodevelopmental outcomes in extremely premature infants who received Prolacta’s 100% human milk-based fortifiers as part of an Exclusive Human Milk Diet, compared with infants fed a cow milk-based diet in the neonatal intensive care unit.

Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.